研究单位：[1]Peking Union Medical College Hospital[2]Beijing Tiantan Hospital[3]Xuanwu Hospital, Beijing[4]Peking University Third Hospital[5]Beijing Hospital[6]Peking University First Hospital[7]Chinese PLA General Hospital
This is a multicenter prospective single arm phase Ib/II study, and the purpose of this study is to evaluate the safety and efficiency of R2-MTX regimen (rituximab & lenalidomide & methotrexate) combined with lenalidomide maintenance in newly-diagnosed primary central nervous system lymphoma. 2-year Progression free survival (PFS) of the cohort is the primary endpoint.
